WO1999065461A2 - Complexes micellaires d'amphiphiles cationiques - Google Patents

Complexes micellaires d'amphiphiles cationiques Download PDF

Info

Publication number
WO1999065461A2
WO1999065461A2 PCT/US1999/013875 US9913875W WO9965461A2 WO 1999065461 A2 WO1999065461 A2 WO 1999065461A2 US 9913875 W US9913875 W US 9913875W WO 9965461 A2 WO9965461 A2 WO 9965461A2
Authority
WO
WIPO (PCT)
Prior art keywords
micellar
lipid
complex
complexes
biologically active
Prior art date
Application number
PCT/US1999/013875
Other languages
English (en)
Other versions
WO1999065461A3 (fr
WO1999065461A9 (fr
Inventor
Jennifer D. Tousignant
Simon J. Eastman
Quiming Chu
Edward R. Lee
Shaona L. Fang
Ronald K. Scheule
Seng H. Cheng
Jannifer B. Nietupski
John Marshall
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Priority to CA002335638A priority Critical patent/CA2335638A1/fr
Priority to JP2000554341A priority patent/JP2002518313A/ja
Priority to AU46984/99A priority patent/AU4698499A/en
Priority to EP99930442A priority patent/EP1085857A2/fr
Publication of WO1999065461A2 publication Critical patent/WO1999065461A2/fr
Publication of WO1999065461A3 publication Critical patent/WO1999065461A3/fr
Publication of WO1999065461A9 publication Critical patent/WO1999065461A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'introduction efficace de gènes étrangers et autres molécules biologiquement actives dans des cellules cible de mammifères reste un défi pour les scientifiques de la profession. La thérapie génique, par exemple, nécessite la transfection réussie de cellules cible chez un patient. La présente invention concerne de nouveaux complexes micellaires de composés amphiphiles cationiques favorisant l'apport de molécules biologiquement actives aux cellules cibles chez un mammifère. Ces nouveaux complexes micellaires comprennent un amphiphile cationique, une molécule biologiquement active, un dérivé du polyéthylène glycol, et éventuellement, un co-lipide. Un autre aspect de l'invention concerne l'utilisation d'agents cible dans n'importe quel procédé permettant l'apport de molécules biologiquement actives dans les cellules de mammifères. Un agent cible est, de façon générale, n'importe quelle molécule, séquence peptidique ou protéine de grande taille ciblant ou se liant de préférence à des cellules de mammifères spécifiques.
PCT/US1999/013875 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques WO1999065461A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002335638A CA2335638A1 (fr) 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques
JP2000554341A JP2002518313A (ja) 1998-06-19 1999-06-18 カチオン性両親媒性ミセル複合体
AU46984/99A AU4698499A (en) 1998-06-19 1999-06-18 Cationic amphiphile micellar complexes
EP99930442A EP1085857A2 (fr) 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8987998P 1998-06-19 1998-06-19
US60/089,879 1998-06-19

Publications (3)

Publication Number Publication Date
WO1999065461A2 true WO1999065461A2 (fr) 1999-12-23
WO1999065461A3 WO1999065461A3 (fr) 2000-02-24
WO1999065461A9 WO1999065461A9 (fr) 2001-02-01

Family

ID=22220044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013875 WO1999065461A2 (fr) 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques

Country Status (5)

Country Link
EP (1) EP1085857A2 (fr)
JP (1) JP2002518313A (fr)
AU (1) AU4698499A (fr)
CA (1) CA2335638A1 (fr)
WO (1) WO1999065461A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062813A2 (fr) * 1999-04-20 2000-10-26 The University Of British Columbia Lipides peg cationiques et méthodes d'utilisation
WO2001080900A2 (fr) * 2000-04-20 2001-11-01 The University Of British Columbia Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
JP2006335772A (ja) * 2006-09-22 2006-12-14 National Institute Of Advanced Industrial & Technology 腸管吸収制御性リポソーム
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
CN102065901B (zh) * 2008-06-19 2013-03-06 日本新药株式会社 药物载体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019738A1 (fr) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Methode de traitement de tissus infectes
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
WO1996014864A1 (fr) * 1994-11-09 1996-05-23 The Regents Of The University Of California Immunoliposomes optimalisant l'incorporation d'un agent dans des cellules cibles
WO1996040964A2 (fr) * 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Particules d'acides nucleiques et de lipides preparees au moyen d'un intermediaire de complexe hydrophobe d'acides nucleiques et de lipides et utilisation pour transferer des genes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
WO1993019738A1 (fr) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Methode de traitement de tissus infectes
WO1996014864A1 (fr) * 1994-11-09 1996-05-23 The Regents Of The University Of California Immunoliposomes optimalisant l'incorporation d'un agent dans des cellules cibles
WO1996040964A2 (fr) * 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Particules d'acides nucleiques et de lipides preparees au moyen d'un intermediaire de complexe hydrophobe d'acides nucleiques et de lipides et utilisation pour transferer des genes

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062813A2 (fr) * 1999-04-20 2000-10-26 The University Of British Columbia Lipides peg cationiques et méthodes d'utilisation
WO2000062813A3 (fr) * 1999-04-20 2001-08-09 Univ British Columbia Lipides peg cationiques et méthodes d'utilisation
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
WO2001080900A2 (fr) * 2000-04-20 2001-11-01 The University Of British Columbia Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
WO2001080900A3 (fr) * 2000-04-20 2003-04-24 Univ British Columbia Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
JP2004508012A (ja) * 2000-04-20 2004-03-18 ザ　ユニバーシティ　オブ　ブリティッシュ　コロンビア エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
JP2006335772A (ja) * 2006-09-22 2006-12-14 National Institute Of Advanced Industrial & Technology 腸管吸収制御性リポソーム
CN102065901B (zh) * 2008-06-19 2013-03-06 日本新药株式会社 药物载体

Also Published As

Publication number Publication date
EP1085857A2 (fr) 2001-03-28
AU4698499A (en) 2000-01-05
CA2335638A1 (fr) 1999-12-23
WO1999065461A3 (fr) 2000-02-24
WO1999065461A9 (fr) 2001-02-01
JP2002518313A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
US20010048940A1 (en) Cationic amphiphile micellar complexes
Mahato et al. Cationic lipid-based gene delivery systems: pharmaceutical perspectives
US5990089A (en) Self-assembling polynucleotide delivery system comprising dendrimer polycations
EP0814777B1 (fr) Complexes stables d'administration de medicaments comprenant des lipides et leur procede de production
CA2163364C (fr) Systeme d'administration auto-elabore de polynucleotides, renfermant des polycations dendrimeres
US6413544B1 (en) Liposome complexes for increased systemic delivery
US6008202A (en) Stable lipid-comprising drug delivery complexes and methods for their production
US7288266B2 (en) Liposome complexes for increased systemic delivery
US6770291B2 (en) Liposome complexes for increased systemic delivery
US5851818A (en) Condensed plasmid-liposome complex for transfection
WO1998051285A2 (fr) Formulations amphiphiles cationiques
JP2000516209A (ja) カチオン性両親媒性物質／ｄｎａ複合体
US6133026A (en) Condensed plasmid-liposome complex for transfection
US6974589B1 (en) Neutral-cationic lipid for nucleic acid and drug delivery
US5942634A (en) Cationic amphiphiles for cell transfections
EP1085857A2 (fr) Complexes micellaires d'amphiphiles cationiques
Uyechi-O’Brien et al. Mechanisms for cationic lipids in gene transfer
HUI et al. FRONTIERS IN HUMAN GENETICS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 46984/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999930442

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 554341

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2335638

Country of ref document: CA

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1999930442

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999930442

Country of ref document: EP